Scope of this summary
Adults with suspected vitamin B12 or folate deficiency because of anemia, macrocytosis, cytopenia, glossitis, neuropathy, gait or cognitive change, dietary risk or malabsorption. Myelodysplasia, acute leukemia, hemolysis, liver disease, hypothyroidism and medication-related macrocytosis require a broader hematology evaluation.
The Bottom Line
- Do not require macrocytosis or anemia before considering vitamin B12 deficiency: neurologic injury, paresthesia, gait disturbance or cognitive change can occur without the classic blood-count pattern and can become irreversible.
- Use CBC, smear and reticulocyte context with serum B12 and folate; when B12 is borderline and suspicion remains, methylmalonic acid can support deficiency but rises with kidney impairment, while homocysteine is less specific and rises with either deficiency.
- Find the cause: pernicious anemia and atrophic gastritis, gastric or ileal surgery, celiac or inflammatory bowel disease, metformin or acid suppression, alcohol, restrictive diet and pregnancy or lactation change replacement and recurrence planning.
- NIH ODS notes that parenteral vitamin B12 is typically used for pernicious anemia, malabsorption and severe deficiency, while small low-quality trials found that very high oral doses can normalize serum B12 similarly to intramuscular therapy; route and dose must follow the diagnosis-specific protocol.
- Assess vitamin B12 before folic-acid monotherapy for an undiagnosed megaloblastic anemia: the US folic-acid label warns that hematologic remission can occur while B12-related neurologic manifestations continue to progress.
Practical clinical workflow
1
Record neurologic, oral and constitutional symptoms, diet, alcohol, pregnancy possibility, GI disease or surgery and medicine exposure; examine gait, vibration and position sense, reflexes, tongue and signs of marrow disease.
2
Obtain CBC with indices, smear, reticulocytes, B12 and folate, adding methylmalonic acid, homocysteine, thyroid, liver, hemolysis and iron studies according to the pattern and kidney function.
3
When the clinical and laboratory pattern supports B12 deficiency, preserve useful pretreatment samples when feasible and investigate pernicious anemia or malabsorption in parallel with treatment under the local protocol.
4
Replace folate after B12 safety is addressed and correct nutrition, alcohol or causal medicines where possible; pregnancy and other high-requirement states need their own preventive and treatment recommendations.
5
Monitor the blood count, neurologic response and adequacy of replacement. The current NASCOBAL label specifically directs potassium and platelet monitoring during intense treatment of severe megaloblastic anemia; apply product-specific labeling rather than generalizing one schedule to every preparation.
Safety boundaries and escalation
- Progressive weakness, ataxia, sphincter symptoms, severe confusion, pancytopenia, hemolysis or cardiovascular compromise from anemia needs urgent assessment and often specialist care.
- A normal folate or B12 result after supplements have started can obscure the pretreatment state; document timing and do not dismiss a compatible neurologic syndrome reflexively.
- Folic acid can interact with anticonvulsant and antifolate treatment, and both NIH ODS and US labeling warn that it can obscure B12-deficient anemia while neurologic injury progresses; review the indication and medicine interactions.
- Persistent unexplained macrocytosis or cytopenias after nutritional correction warrants hematology evaluation for marrow disease rather than indefinite vitamin escalation.
Localization
No single current US national clinical-practice guideline covers this combined diagnostic and treatment topic. This summary is therefore limited to NIH ODS evidence summaries and current DailyMed label safety; it does not turn one product label into a universal dosing regimen.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- National Institutes of Health Office of Dietary SupplementsVitamin B12: Fact Sheet for Health Professionalsupdated 2025-07-02 路 accessed 2026-08-20view source
- National Institutes of Health Office of Dietary SupplementsFolate: Fact Sheet for Health Professionalsupdated 2022-11-30 路 accessed 2026-08-20view source
- U.S. National Library of Medicine DailyMedNASCOBAL (cyanocobalamin) nasal spray: Full Prescribing Informationupdated 2024-03-01 路 accessed 2026-08-20view source
- U.S. National Library of Medicine DailyMedFolic Acid tablet: Drug Label Informationupdated 2023-07-11 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.